isonicotinyl-nad and Tuberculosis--Pulmonary

isonicotinyl-nad has been researched along with Tuberculosis--Pulmonary* in 1 studies

Other Studies

1 other study(ies) available for isonicotinyl-nad and Tuberculosis--Pulmonary

Article	Year
A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 One of the most effective and widely used antituberculosis (anti-TB) drugs is isoniazid (INH), a prodrug activated via oxidation that forms an adduct with NAD(+) to inhibit NADH-dependent targets of Mycobacterium tuberculosis, such as enoyl-acyl carrier protein reductase (InhA). The metabolic by-products and potentially toxic intermediates resulting from INH therapy have been identified through a large body of work. However, an INH-NAD adduct or structures related to this adduct have not been identified in specimens from human TB patients or animal models of TB. Analyses by mass spectrometry of urine collected from TB patients in a study conducted by the NIAID-funded Tuberculosis Research Unit identified 4-isonicotinoylnicotinamide (C(12)H(9)N(3)O(2)) as a novel metabolite of INH therapy. This compound was formed by M. tuberculosis strains in a KatG-dependent manner but could also be produced by mice treated with INH independent of an M. tuberculosis infection. Thus, the 4-isonicotinoylnicotinamide observed in human urine samples is likely derived from the degradation of oxidized INH-NAD adducts and provides direct evidence of host INH activation. Topics: Animals; Antitubercular Agents; Bacterial Proteins; Biotransformation; Catalase; Chromatography, Liquid; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; NAD; Oxidation-Reduction; Oxidoreductases; Tuberculosis, Pulmonary	2012

Article

Year

A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

One of the most effective and widely used antituberculosis (anti-TB) drugs is isoniazid (INH), a prodrug activated via oxidation that forms an adduct with NAD(+) to inhibit NADH-dependent targets of Mycobacterium tuberculosis, such as enoyl-acyl carrier protein reductase (InhA). The metabolic by-products and potentially toxic intermediates resulting from INH therapy have been identified through a large body of work. However, an INH-NAD adduct or structures related to this adduct have not been identified in specimens from human TB patients or animal models of TB. Analyses by mass spectrometry of urine collected from TB patients in a study conducted by the NIAID-funded Tuberculosis Research Unit identified 4-isonicotinoylnicotinamide (C(12)H(9)N(3)O(2)) as a novel metabolite of INH therapy. This compound was formed by M. tuberculosis strains in a KatG-dependent manner but could also be produced by mice treated with INH independent of an M. tuberculosis infection. Thus, the 4-isonicotinoylnicotinamide observed in human urine samples is likely derived from the degradation of oxidized INH-NAD adducts and provides direct evidence of host INH activation.

Topics: Animals; Antitubercular Agents; Bacterial Proteins; Biotransformation; Catalase; Chromatography, Liquid; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; NAD; Oxidation-Reduction; Oxidoreductases; Tuberculosis, Pulmonary

2012